BRIEF-Abbvie Says FDA Approves Treatment For Intra-Abdominal Infections

Reuters
08 Feb
BRIEF-Abbvie Says FDA Approves Treatment For Intra-Abdominal Infections

Feb 7 (Reuters) - Abbvie Inc ABBV.N:

  • U.S. FDA APPROVES EMBLAVEO™ (AZTREONAM AND AVIBACTAM) FOR THE TREATMENT OF ADULTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS WITH LIMITED OR NO TREATMENT OPTIONS

  • ABBVIE INC - EMBLAVEO AVAILABLE IN U.S. IN Q3 2025

Source text: ID:nPn8vH21Ca

Further company coverage: ABBV.N

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10